|Day Low/High||15.60 / 16.32|
|52 Wk Low/High||11.45 / 46.17|
Insys Therapeutics (INSY) stock is trading sharply higher this afternoon after receiving FDA approval for Syndros.
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a pre-market mover with heavy volume candidate
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Investors eyeing a purchase of Insys Therapeutics Inc shares, but cautious about paying the going market price of $15.88/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $11 strike, which has a bid at the time of this writing of 85 cents.
Weed has gone from a taboo substance to a multi-billion-dollar bonanza. The growth of the marijuana sector has created opportunities for investors. Here are four to watch.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The burgeoning marijuana industry is ramping up its efforts to attract both institutional and typical investors by attempting to list on the Nasdaq and through crowdsourcing.
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Investors choosing among the hundreds of cannabis businesses are often caught in a conundrum as to whether medical companies are a safer investment compared to recreational businesses.
Companies are seeking options for mainstream investors to get high gains. Americans can invest in multiple businesses traded publicly on the Nasdaq or take a private investment approach.
The medical marijuana business should rack up smoking gains. We've pinpointed the three stocks that will benefit the most.
Cramer says stay away from Prospect Capital but buy WebMD Health.
The rolling bear market is getting replaced by something new, a revolving bull market, Cramer says.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Insys Therapeutics Inc , where a total volume of 4,944 contracts has been traded thus far today, a contract volume which is representative of approximately 494,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56% of INSY's average daily trading volume over the past month, of 882,400 shares.
Insys Therapeutics (INSY) stock is plummeting in late-afternoon trading on Monday after the company reported preliminary first quarter revenues for its Subsys treatment.
Shares of Endo fall as much as 9% Monday in sympathy with Insys Therapeutics, which pre-announced sharply weaker first-quarter sales of its fentanyl painkiller Subsys.
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a weak on high relative volume candidate
Law Offices of Howard G. Smith reminds investors of the upcoming April 4, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Insys Therapeutics, Inc.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of INSYS Therapeutics, Inc.